Tumor necrosis factor-costimulated T lymphocytes from patients with systemic sclerosis trigger collagen production in fibroblasts

Arthritis and Rheumatism

Volumn 65, Issue 2, 2013, Pages 481-491

  Hügle, Thomas ^a,b   O'Reilly, Steven ^a   Simpson, Rachel ^a   Kraaij, Marina D ^a   Bigley, Venetia ^a   Collin, Matthew ^a   Krippner Heidenreich, Anja ^a   Van Laar, Jacob M ^a  

^a NEWCASTLE UNIVERSITY   (United Kingdom)

^b UNIVERSITY HOSPITAL BASEL   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

CD28 ANTIGEN; CD3 ANTIGEN; COLLAGEN; COLLAGEN TYPE 1; INTERLEUKIN 10; INTERLEUKIN 13; INTERLEUKIN 6; LIGAND; TUMOR NECROSIS FACTOR;

ADULT; ARTICLE; BLOOD; CLINICAL ARTICLE; DERMIS; ENZYME LINKED IMMUNOSORBENT ASSAY; FIBROBLAST; FLOW CYTOMETRY; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMAN; HUMAN CELL; HUMAN TISSUE; INFLAMMATION; LYMPHOCYTE ACTIVATION; MONONUCLEAR CELL; PRIORITY JOURNAL; PROTEIN EXPRESSION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SUPERNATANT; SYSTEMIC SCLEROSIS; T LYMPHOCYTE; UPREGULATION;

ADULT; COLLAGEN; FIBROBLASTS; HUMANS; INTERLEUKIN-13; INTERLEUKIN-6; RECEPTORS, INTERLEUKIN-6; RECEPTORS, TUMOR NECROSIS FACTOR; SCLERODERMA, SYSTEMIC; T-LYMPHOCYTES; TUMOR NECROSIS FACTOR-ALPHA;

EID: 84873832733     PISSN: 00043591     EISSN: 15290131     Source Type: Journal    
DOI: 10.1002/art.37738     Document Type: Article

References (49)

1. Varga J, Abraham D,. Systemic sclerosis: a prototypic multisystem fibrotic disorder. J Clin Invest 2007; 117: 557-67.
2. Fleischmajer R, Perlish JS, West WP,. Ultrastructure of cutaneous cellular infiltrates in scleroderma. Arch Dermatol 1977; 113: 1661-6.
3. Hugle T, Hogan V, White KE, van Laar JM,. Mast cells are a source of transforming growth factor β in systemic sclerosis. Arthritis Rheum 2011; 63: 795-9.
4. Kalogerou A, Gelou E, Mountantonakis S, Settas L, Zafiriou E, Sakkas L,. Early T cell activation in the skin from patients with systemic sclerosis. Ann Rheum Dis 2005; 64: 1233-5.
5. Roumm AD, Whiteside TL, Medsger TA Jr, Rodnan GP,. Lymphocytes in the skin of patients with progressive systemic sclerosis: quantification, subtyping, and clinical correlations. Arthritis Rheum 1984; 27: 645-53.
6. Sakkas LI, Xu B, Artlett CM, Lu S, Jimenez SA, Platsoucas CD,. Oligoclonal T cell expansion in the skin of patients with systemic sclerosis. J Immunol 2002; 168: 3649-59.
7. Mavalia C, Scaletti C, Romagnani P, Carossino AM, Pignone A, Emmi L, et al. Type 2 helper T-cell predominance and high CD30 expression in systemic sclerosis. Am J Pathol 1997; 151: 1751-8.
8. Whiteside TL, Kumagai Y, Roumm AD, Almendinger R, Rodnan GP,. Suppressor cell function and T lymphocyte subpopulations in peripheral blood of patients with progressive systemic sclerosis. Arthritis Rheum 1983; 26: 841-7.
9. O'Reilly S, Hugle T, van Laar J,. T cells in systemic sclerosis: a reappraisal. Rheumatology (Oxford) 2012; 51: 1540-9.
10. Radstake TR, van Bon L, Broen J, Wenink M, Santegoets K, Deng Y, et al. Increased frequency and compromised function of T regulatory cells in systemic sclerosis (SSc) is related to a diminished CD69 and TGFβ expression. PLoS One 2009; 4: e5981.
11. Papp G, Horvath IF, Barath S, Gyimesi E, Sipka S, Szodoray P, et al. Altered T-cell and regulatory cell repertoire in patients with diffuse cutaneous systemic sclerosis. Scand J Rheumatol 2011; 40: 205-10.
12. Antiga E, Quaglino P, Bellandi S, Volpi W, Del Bianco E, Comessatti A, et al. Regulatory T cells in the skin lesions and blood of patients with systemic sclerosis and morphoea. Br J Dermatol 2010; 162: 1056-63.
13. Wilson MS, Elnekave E, Mentink-Kane MM, Hodges MG, Pesce JT, Ramalingam TR, et al. IL-13Rα2 and IL-10 coordinately suppress airway inflammation, airway-hyperreactivity, and fibrosis in mice. J Clin Invest 2007; 117: 2941-51.
14. Chizzolini C, Brembilla NC, Montanari E, Truchetet ME,. Fibrosis and immune dysregulation in systemic sclerosis. Autoimmun Rev 2011; 10: 276-81.
15. Abe R, Donnelly SC, Peng T, Bucala R, Metz CN,. Peripheral blood fibrocytes: differentiation pathway and migration to wound sites. J Immunol 2001; 166: 7556-62.
16. Phelps RG, Daian C, Shibata S, Fleischmajer R, Bona CA,. Induction of skin fibrosis and autoantibodies by infusion of immunocompetent cells from tight skin mice into C57BL/6 Pa/Pa mice. J Autoimmun 1993; 6: 701-18.
17. Chen X, Baumel M, Mannel DN, Howard OM, Oppenheim JJ,. Interaction of TNF with TNF receptor type 2 promotes expansion and function of mouse CD4+CD25+ T regulatory cells. J Immunol 2007; 179: 154-61.
18. Kassiotis G, Kollias G,. Uncoupling the proinflammatory from the immunosuppressive properties of tumor necrosis factor (TNF) at the p55 TNF receptor level: implications for pathogenesis and therapy of autoimmune demyelination. J Exp Med 2001; 193: 427-34.
19. Theiss AL, Simmons JG, Jobin C, Lund PK,. Tumor necrosis factor (TNF) α increases collagen accumulation and proliferation in intestinal myofibroblasts via TNF receptor 2. J Biol Chem 2005; 280: 36099-109.
20. Gruschwitz MS, Albrecht M, Vieth G, Haustein UF,. In situ expression and serum levels of tumor necrosis factor-α receptors in patients with early stages of systemic sclerosis. J Rheumatol 1997; 24: 1936-43.
21. Oikonomou N, Harokopos V, Zalevsky J, Valavanis C, Kotanidou A, Szymkowski DE, et al. Soluble TNF mediates the transition from pulmonary inflammation to fibrosis. PLoS One 2006; 1: e108.
22. Ortiz LA, Lasky J, Hamilton RF Jr, Holian A, Hoyle GW, Banks W, et al. Expression of TNF and the necessity of TNF receptors in bleomycin-induced lung injury in mice. Exp Lung Res 1998; 24: 721-43.
23. Smith RE, Strieter RM, Phan SH, Kunkel SL,. C-C chemokines: novel mediators of the profibrotic inflammatory response to bleomycin challenge. Am J Respir Cell Mol Biol 1996; 15: 693-702.
24. Oikonomou N, Harokopos V, Zalevsky J, Valavanis C, Kotanidou A, Szymkowski DE, et al. Soluble TNF mediates the transition from pulmonary inflammation to fibrosis. PLoS One 2006; 1: e108.
25. Walter N, Collard HR, King TE Jr,. Current perspectives on the treatment of idiopathic pulmonary fibrosis. Proc Am Thorac Soc 2006; 3: 330-8.
26. Lam GK, Hummers LK, Woods A, Wigley FM,. Efficacy and safety of etanercept in the treatment of scleroderma-associated joint disease. J Rheumatol 2007; 34: 1636-7.
27. Denton CP, Engelhart M, Tvede N, Wilson H, Khan K, Shiwen X, et al. An open-label pilot study of infliximab therapy in diffuse cutaneous systemic sclerosis. Ann Rheum Dis 2009; 68: 1433-9.
28. Distler JH, Schett G, Gay S, Distler O,. The controversial role of tumor necrosis factor α in fibrotic diseases [review]. Arthritis Rheum 2008; 58: 2228-35.
29. Chizzolini C, Parel Y, De Luca C, Tyndall A, Akesson A, Scheja A, et al. Systemic sclerosis Th2 cells inhibit collagen production by dermal fibroblasts via membrane-associated tumor necrosis factor α. Arthritis Rheum 2003; 48: 2593-604.
30. Black RA, Rauch CT, Kozlosky CJ, Peschon JJ, Slack JL, Wolfson MF, et al. A metalloproteinase disintegrin that releases tumour-necrosis factor-α from cells. Nature 1997; 385: 729-33.
31. Grell M, Douni E, Wajant H, Lohden M, Clauss M, Maxeiner B, et al. The transmembrane form of tumor necrosis factor is the prime activating ligand of the 80 kDa tumor necrosis factor receptor. Cell 1995; 83: 793-802.
32. Chen X, Oppenheim JJ,. TNF-α: an activator of CD4+FoxP3+TNFR2+ regulatory T cells. Curr Dir Autoimmun 2010; 11: 119-34.
33. Tartaglia LA, Goeddel DV, Reynolds C, Figari IS, Weber RF, Fendly BM, et al. Stimulation of human T-cell proliferation by specific activation of the 75-kDa tumor necrosis factor receptor. J Immunol 1993; 151: 4637-41.
34. Subcommittee for Scleroderma Criteria of the American Rheumatism Association Diagnostic and Therapeutic Criteria Committee. Preliminary criteria for the classification of systemic sclerosis (scleroderma). Arthritis Rheum 1980; 23: 581-90.
35. Haniffa M, Ginhoux F, Wang XN, Bigley V, Abel M, Dimmick I, et al. Differential rates of replacement of human dermal dendritic cells and macrophages during hematopoietic stem cell transplantation. J Exp Med 2009; 206: 371-85.
36. Krippner-Heidenreich A, Tubing F, Bryde S, Willi S, Zimmermann G, Scheurich P,. Control of receptor-induced signaling complex formation by the kinetics of ligand/receptor interaction. J Biol Chem 2002; 277: 44155-63.
37. Ward C, Eger K, Diboll J, Jones D, Haniffa MA, Brodlie M, et al. Bronchial epithelial cells cultured from clinically stable lung allograft patients promote the development of macrophages from monocytes rather than dendritic cells. Thorax 2009; 64: 430-5.
38. Clements P, Lachenbruch P, Seibold J, White B, Weiner S, Martin R, et al. Inter and intraobserver variability of total skin thickness score (modified Rodnan TSS) in systemic sclerosis. J Rheumatol 1995; 22: 1281-5.
39. Scheurich P, Thoma B, Ucer U, Pfizenmaier K,. Immunoregulatory activity of recombinant human tumor necrosis factor (TNF)-α: induction of TNF receptors on human T cells and TNF-α-mediated enhancement of T cell responses. J Immunol 1987; 138: 1786-90.
40. Villiger PM, Cronin MT, Amenomori T, Wachsman W, Lotz M,. IL-6 production by human T lymphocytes: expression in HTLV-1-infected but not in normal T cells. J Immunol 1991; 146: 550-9.
41. Pantelidis P, Fanning GC, Wells AU, Welsh KI, du Bois RM,. Analysis of tumor necrosis factor-α, lymphotoxin-α, tumor necrosis factor receptor II, and interleukin-6 polymorphisms in patients with idiopathic pulmonary fibrosis. Am J Respir Crit Care Med 2001; 163: 1432-6.
42. Medsger TA Jr, Ivanco DE, Kardava L, Morel PA, Lucas MR, Fuschiotti P,. GATA-3 up-regulation in CD8+ T cells as a biomarker of immune dysfunction in systemic sclerosis, resulting in excessive interleukin-13 production. Arthritis Rheum 2011; 63: 1738-47.
43. Ndhlovu LC, Ishii N, Murata K, Sato T, Sugamura K,. Critical involvement of OX40 ligand signals in the T cell priming events during experimental autoimmune encephalomyelitis. J Immunol 2001; 167: 2991-9.
44. Ohshima Y, Yang LP, Uchiyama T, Tanaka Y, Baum P, Sergerie M, et al. OX40 costimulation enhances interleukin-4 (IL-4) expression at priming and promotes the differentiation of naive human CD4(+) T cells into high IL-4-producing effectors. Blood 1998; 92: 3338-45.
45. Gourh P, Arnett FC, Tan FK, Assassi S, Divecha D, Paz G, et al. Association of TNFSF4 (OX40L) polymorphisms with susceptibility to systemic sclerosis. Ann Rheum Dis 2010; 69: 550-5.
46. Nam KO, Shin SM, Lee HW,. Cross-linking of 4-1BB up-regulates IL-13 expression in CD8(+) T lymphocytes. Cytokine 2006; 33: 87-94.
47. O'Donoghue RJ, Knight DA, Richards CD, Prele CM, Lau HL, Jarnicki AG, et al. Genetic partitioning of interleukin-6 signalling in mice dissociates Stat3 from Smad3-mediated lung fibrosis. EMBO Mol Med 2012; 4: 939-51.
48. Prele CM, Yao E, O'Donoghue RJ, Mutsaers SE, Knight DA,. STAT3: a central mediator of pulmonary fibrosis? Proc Am Thorac Soc 2012; 9: 177-82.
49. Sargent JL, Milano A, Bhattacharyya S, Varga J, Connolly MK, Chang HY, et al. A TGFβ-responsive gene signature is associated with a subset of diffuse scleroderma with increased disease severity. J Invest Dermatol 2010; 130: 694-705.